Revance to Participate in the Needham 22nd Annual Healthcare Conference
Revance Therapeutics, Inc. (NASDAQ: RVNC) will participate in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity.
Revance is headquartered in
“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of
Resilient Hyaluronic Acid® and RHA® are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20230405005155/en/
Investors
jessica.serra@revance.com
or
laurence@gilmartinir.com
Media
sfahy@revance.com
Source: